Skip to main content
SpringerLink
Log in

Initial management of proliferative lupus nephritis: To cytotoxic or not to cytotoxic?

  • Invited Commentary
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Austin Ha, Klippel JH, Balow JE, et al.: The Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Eng J Med 1986, 314:614–619.

    Article  Google Scholar 

  2. Boumpas DT, Austin HA III, Vaughn EM, et al.: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992, 340:741–745.

    Article  PubMed  CAS  Google Scholar 

  3. Belmont HM, Storch M, Buyon J, Abramson S: New York University/Hospital for Joint Diseases experience with intra-venous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus 1995, 4:104–108.

    PubMed  CAS  Google Scholar 

  4. Pistiner M, Wallace DJ, Nessim S, et al.: Lupus erythematosus in the 1980s: a surey of 570 patients. Semin Rheum Dis 1991, 21:55–64.

    Article  CAS  Google Scholar 

  5. McCune WJ, Golbus J, Zeldes W, et al.: Clinical and immuno-logic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Eng J Med 1988, 318:1423–1451.

    Article  CAS  Google Scholar 

  6. Du LTH, Piette JC, Faucher C, et al.: Efficacy and limits of intra-venous cyclophosphamide (IVCP) in systemic lupus erythe-matosus (SLE): an open study in 45 cases [abstract]. Arthritis Rheum 1991, 34:S58.

    Google Scholar 

  7. Lehman TJA, Sherry DD, Wagner-Weiner L, et al.: Intermittent intravenous cyclophosphamide for lupus nephritis. J Pediatr 1989, 114:1055–1060.

    Article  PubMed  CAS  Google Scholar 

  8. Wagner-Weiner L, Emery H, Spencer C, et al.: Intravenous pulse cyclophosphamide therapy (IVCY) for childhood lupus nephritis: variable renal outcomes at 3 to 7 year follow-up [abstract]. Arthritis Rheum 1991, 34:S58.

    Article  Google Scholar 

  9. Gourley MF, Austin HA, Scott D, et al.: Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann Intern Med 1997, 125:549–557.

    Google Scholar 

  10. Felson DT, Anderson J: Evidence for the superiority of immuno-suppresive drugs and prednisone over prednisone alone in lupus nephritis: results of a pooled analysis. N Eng J Med 1984, 311:1528–1533.

    Article  CAS  Google Scholar 

  11. Bansal VK, Beto JA: Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 1997, 29:193–199.

    PubMed  CAS  Google Scholar 

  12. Steinberg AD, Steinberg SC: Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone alone. Arthritis Rheum 1991, 34:945–950.

    Article  PubMed  CAS  Google Scholar 

  13. Briggs WA, Choi MJ, Schesel PJ Jr: Successful mycophenolate mofetil treatment of glomerular diseases. Am J Kidney Dis 1998, 41:S110.

    Google Scholar 

  14. Pashinian N, Wallace D, Klineneberg JR: Mycophenolate mofetil for systemic lupus erythematosus. Arthritis Rheum 1998, 41:S110.

    Article  Google Scholar 

  15. Lewis EJ, Hunsicker LG, Lan SP, et al.: A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Eng J Med 1992, 326:1373–1379.

    Article  CAS  Google Scholar 

  16. Euler HH, Gutschmidt HJ, Schmuecking M, et al.: Induction of remission in severe SLE after plasma exchange synchronized with subsequent pulse cyclophosphamide. Prog Clin Biol Res 1990, 337:319–320.

    PubMed  CAS  Google Scholar 

  17. Wallace D, Goldfinger D, Pepkowitz S: A prospective, con-trolled trial of pulse synchronization cyclophosphamide (CTX)/apheresis for proliferative lupus nephritis [abstract]. Arthritis Rheum 1997, 40:S58.

    Google Scholar 

  18. Schroeder JO, Schwab U, Zeuner R, et al.: Plasmapheresis and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus. Arthritis Rheum 1997, 40:S325.

    Google Scholar 

  19. Marmont AM: Intense immunosuppression and stem cell transplantation or rescue for severe systemic lupus erythema-tosus. Lupus 1999, 8:256–257.

    Article  PubMed  CAS  Google Scholar 

  20. Brodsky RA, Petri M, Smith BD, et al.: Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory severe autoimmune disease. Ann Intern Med 1998, 129:1031–1035.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, Hospital for Joint Diseases, 301 East 17th Street, New York, NY

    H. Michael Belmont MD

Authors
  1. H. Michael Belmont MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Belmont, H.M. Initial management of proliferative lupus nephritis: To cytotoxic or not to cytotoxic?. Curr Rheumatol Rep 1, 87–88 (1999). https://doi.org/10.1007/s11926-999-0001-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-999-0001-9

Keywords

Search

Navigation